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Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac
arrhythmia syndrome that often leads to sudden cardiac death. The most common
form of CPVT is caused by autosomal-dominant variants in the cardiac ryanodine
receptor type-2 (RYR2) gene. Mutations in RYR2 promote calcium (Ca2+) leak from the
sarcoplasmic reticulum (SR), triggering lethal arrhythmias. Recently, it was demonstrated that tetracaine derivative EL20 specifically inhibits mutant RyR2, normalizes
Ca2+ handling and suppresses arrhythmias in a CPVT mouse model. The objective
of this study was to determine whether EL20 normalizes SR Ca2+ handling and arrhythmic events in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs)
from a CPVT patient. Blood samples from a child carrying RyR2 variant RyR2 variant Arg-176-Glu (R176Q) and a mutation-negative relative were reprogrammed into
iPSCs using a Sendai virus system. iPSC-CMs were derived using the Stemdiff TM kit.
Confocal Ca2+ imaging was used to quantify RyR2 activity in the absence and presence of EL20. iPSC-CMs harbouring the R176Q variant demonstrated spontaneous
SR Ca2+ release events, whereas administration of EL20 diminished these abnormal
events at low nanomolar concentrations (IC50 = 82 nM). Importantly, treatment with

EL20 did not have any adverse effects on systolic Ca2+ handling in control iPSC-CMs.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
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Our results show for the first time that tetracaine derivative EL20 normalized SR Ca2+
handling and suppresses arrhythmogenic activity in iPSC-CMs derived from a CPVT
patient. Hence, this study confirms that this RyR2-inhibitor represents a promising
therapeutic candidate for treatment of CPVT.
KEYWORDS

Catecholaminergic polymorphic ventricular tachycardia, induced pluripotent stem cells,
ryanodine receptors, RyR2, tetracaine, ventricular arrhythmia

1 | I NTRO D U C TI O N

model.13 The half-maximum inhibitory concentration of EL20 in mouse
myocytes was 35.4 mmol/L,13 which was an order of magnitude better

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-

than that of another well-studied RyR2 inhibitor JTV519 (K201).12 This tet-

threatening inherited cardiac arrhythmia syndrome that can lead to sudden

racaine derivative does not block Na+ or IKr channels within the effective

cardiac arrest and death at a very high rate if left untreated. It is character-

concentration range used to inhibit RyR2 channels and has a favourable

ized by polymorphic and/or bi-directional ventricular tachycardia (VT) that

plasma stability profile (data not shown). In addition, tetracaine derivatives

is triggered by β-adrenergic stimulation associated with vigorous exercise

appear to work for all gain-of-function RyR2 variants, which represent the

or emotional stress.1 The prevalence of CVPT is estimated to be around

vast majority (>95%) of all known CPVT-causing variants (>150 described

1:5000 to 1:10 000; both sexes are affected equally. The most common

to date). It remains unclear, however, whether a compound like EL20 also

form of CPVT is caused by autosomal-dominant variants in the RYR2 gene

normalizes CPVT-mutant RyR2 in human cardiac myocytes. Therefore,

2,3

The RyR2 channel re-

we developed induced pluripotent stem cell-derived cardiomyocytes

leases Ca2+ from the sarcoplasmic reticulum (SR) in response to electrical

encoding the cardiac ryanodine receptor type-2.

(iPSC-CMs) from a CPVT patient carrying the same R176Q variant in

excitation of the plasma membrane, which leads to influx of Ca2+ via the

RYR2. Confocal imaging revealed that EL20 effectively suppresses the

L-type Ca2+ channel. Variants in RYR2 promote diastolic SR Ca2+ leak which

enhanced Ca2+ spark frequency observed in iPSC-CMs from this CPVT

1,4

causes triggered activity and can initiate arrhythmias seen in CPVT.

Although CVPT is one of the most lethal forms of inherited cardiac

patient. These findings suggest that this RyR2-inhibitor represents a
promising therapeutic candidate for treatment of CPVT patients.

disease, current treatment options remain limited. β-adrenoreceptor
blockers only control symptoms and suppress arrhythmias in about
30%-50% of patients.5 Flecainide—a class 1C Na+ channel blocker
that also normalizes RyR2 activity—has shown potential in CPVT
patients but also has a black box warning for patients with any kind

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Human subject recruitment

of structural heart disease.6,7 Implantable cardioverter-defibrillators
(ICDs) are used in the event of severe or recurrent arrhythmias, but

All studies were approved by the Baylor College of Medicine IRB

ICD discharges may further aggravate catecholamine release and lead

and follow the Declaration of Helsinki guidelines. Subjects were

to electrical storm.8 Hence, there remains an unmet need to develop

evaluated by a paediatric electrophysiologist and a history, physical

new pharmacological or biological agents for the treatment of CPVT

examination, echocardiogram, electrocardiogram and ancillary test-

that specifically correct disease-causing molecular defects.

ing were performed. Following written receipt of informed consent,

Several classes of drugs have been developed that target mutant

whole blood was obtained from the proband and kindred.

or dysfunctional RyR2 channels.9 These include, among others, benzothiazepine derivatives (K201, S107),10,11 tetracaine derivatives (EL9,
EL20),12,13 class 1C anti-arrhythmic drug derivatives of flecainide and

2.2 | Cardiac differentiation of iPSCs

propafenone,14 hydantoin derivatives (such as dantrolene),15 non-
beta blocking carvedilol derivatives16 and unnatural verticilide enan-

iPSCs were differentiated into iPSC-CMs using the STEMdiffTM CM dif-

tiomers.17 The efficacy of these compounds have been evaluated in

ferentiation kit (Stemcell Technologies) according to the company pro-

various knock-in mouse models carrying RyR2 variants or calseques-

tocol (Document #DX21496). See Supplemental Methods for details.

trin-2 variants/knockout.11,12,14,18 For example, mice heterozygous for
RyR2 variant RyR2 variant Arg-176-Glu (R176Q) are susceptible to
ventricular tachycardia after injection of caffeine and epinephrine, or

2.3 | Dissociation and plating of mature iPSC-CMs

following programmed ventricular stimulation and administration of
β-adrenergic receptor agonist isoproterenol (ISO).18
We recently demonstrated that tetracaine derivative EL20 can normalize aberrant SR Ca2+ leak associated with CPVT in the R176Q mouse

Spontaneously beating CMs were dissociated using the STEMDiff TM
Cardiomyocyte Dissociation Kit (Stemcell Technologies; Document
#DX21497). See Supplemental Methods for details.

|
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F I G U R E 1 Pedigree and clinical
phenotype of catecholaminergic
polymorphic ventricular tachycardia
(CPVT) patient: A, 14-year-old proband
and kindred. The CPVT proband is
identified by a black arrow, and the R176Q
variant in RYR2 is denoted by a filled black
symbol (± represents heterozygosity for
the R176Q variant). Unaffected family
members are shown as open symbols.
Family members with a history of sudden
cardiac arrest who were not genetically
tested are shown as striped symbols. Line
through symbol represents deceased
family member. B, Schematic of RyR2
protein highlighting R176Q mutation
(red). C, Standard resting 12-lead ECG
of the proband showing normal activity.
D, Episode of polymorphic ventricular
ectopy following epinephrine challenge in
proband

2.4 | EL20 synthesis

sparks were recorded in line-scan mode using a LSM880 confocal
microscope (Carl Zeiss). CaSpF was assessed with ImageJ software

The tetracaine derivative, 2-(diethylamino)ethyl 4-butlamino)-2methoxy-

using SparkMaster plugin. See Supplemental Methods for details.

benzoate, also known as EL20, was synthesized using a two-step synthesis route as previously described by Klipp et al.13

2.5 | Ca2+ imaging of iPSC-CMs and drug treatment
using EL20

2.6 | Statistical analysis
Results are expressed as mean ± SEM. For clustered data in which
continuous variables were observed, the generalized estimating
equation was used via SPSS version 24 (IBM) or Prism 8 (GraphPad)

For drug assay studies, iPSC-CMs were incubated with drug (con-

using an unpaired Student's t test or ANOVA, after performing the

centration range 0.5 nmol/L-5 μmol/L) for 30 minutes at 37°C. Ca2+

D’Agostino-Pearson normality test for normal data distribution.

4
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For multiple group comparison, two-way ANOVA followed by

(Figure S3). CPVT proband and control-d erived iPSCs were dif-

Tukey's post-test was used. P < .05 was considered statistically

ferentiated into CMs that contracted spontaneously as coordi-

significant.

nated sheets observed under light microscopy (Figure S4A,B).
iPSC-C Ms dissociated into single cells from both lines main-

3 | R E S U LT S
3.1 | Clinical evaluation of CPVT proband

tained spontaneous contraction. qPCR demonstrated down-
regulation of the pluripotency markers and SOX2 (Tables S1
and S2; Figure S4C) and up-r egulation of the cardiac and Ca 2+
handling markers (Table S2; Figure S4C). Immunofluorescence
exhibited positive staining for similar cardiac and ca 2+ handling

The patient was previously a seemingly healthy female with a

markers (Table S3; Figure S4D).

family history of sudden cardiac death (Figure 1A,B). Her maternal grandmother died postpartum at the age of 23 years, after
giving birth to the proband's mother. The proband's mother suffered an aborted cardiac arrest at the age of 19 and again at the

3.3 | CPVT patient-derived iPSC-CMs exhibit
spontaneous and evoked Ca2+ transients

age of 35 that consequently left her in a persistent vegetative
state. The proband underwent cardiac evaluation at the age of 14

Previous studies revealed that beating clusters of iPSC-CMs con-

and was found to have a structurally normal heart with normal bi-

tain a mixture of ventricular, atrial and sinus node-like cell popu-

ventricular function by echocardiogram (Figure S1). Her 12-lead

lations based on their action potential (AP) phenotypes.19 Here,

resting ECGs revealed a normal heart rate (54 beats per minute),

we used confocal Ca2+ imaging to characterized intracellular Ca2+

normal PR interval (144 ms), normal QT interval (410 ms) and a

handling in dissociated iPSC-CMs that exhibited a ventricular-t ype

normal corrected QT interval (QTc of 389 ms) (Figure 1C). She

morphology. About 50% of iPSC-CMs exhibited non-evoked, spon-

had no prior history of syncope and denied any cardiac symp-

taneous rhythmic beating without electrical stimulation (Figure 2A).

toms. A few months after initial evaluation, the patient suffered

The average spontaneous beating rate of non-evoked iPSC-CMs

an aborted cardiac arrest after running home from school. She

with the R176Q mutation was 80.8 ± 8.4/min vs control iPSC-

was found to be in ventricular fibrillation with return of sponta-

CMs 41.6 ± 8.4/min (P = .002) consistent with being arrhythmic

neous circulation after successful defibrillation. During hospital

(Figure S5). In addition, 60% (6 out of 10 cells) of non-evoked R176Q

admission, she was noted to have bi-d irectional premature ven-

iPSC-CM exhibited irregular Ca2+ waveforms following completion

tricular contractions during periods of stimulation. Due to sus-

of the Ca2+ transient, thus resembling events that could initiate de-

picion of CPVT, she underwent an epinephrine challenge which

layed afterdepolarizations (DADs). The amplitudes of non-evoked

revealed bi-d irectional VT and was subsequently diagnosed with

Ca2+ transients were similar between the groups (F/F0 in R176Q:

CPVT (Figure 1D). Genetic testing confirmed a heterozygous

1.7 ± 0.35 vs control: 1.9 ± 0.33; P = .64) (Figure 2B). The SR Ca2+

pathogenic missense mutation in RYR2 (c.527G>A, p.Arg176Gln

load assessed by a caffeine dump protocol was found to be simi-

and R176Q). The CPVT proband is currently being treated with

lar between both groups (F/F0 in R176Q: 2.2 ± 0.24 vs control:

a β-b locker and has an ICD. Her father (41-year-o ld) is an unaf-

2.6 ± 0.88 and P = .37) (Figure 2C). Next, we performed electrical

fected family member and is considered a healthy, mutation-

field stimulation to characterize iPSC-CMs that were not spontane-

negative control.

ously active under baseline conditions. About 75% of the iPSC-CMs
that did not spontaneously beat at baseline followed the 1-Hz pac-

3.2 | Development, characterization and cardiac
differentiation of iPSCs

ing train (Figure 2D); the remainder of the cells did not exhibit SR
Ca2+ release upon electrical stimulation. While similar number of
iPSC-CMs with the R176Q variant responded to electrical stimulation, 63% of those iPSC-CMs exhibited aberrant SR Ca2+ release

Blood from the CPVT proband and mutation-n egative fa-

patterns characterized by Ca2+ oscillations during the Ca2+ transient

ther was collected, and peripheral blood mononuclear cells

decay phase, that resemble those seen in conjunction with early

(PBMCs) were extracted and subsequently reprogrammed

afterdepolarizations (EADs). Finally, the amplitude of the Ca2+ tran-

into iPSCs using Sendai viruses (Figure S2A-D ). Both cell lines

sients (F/F0 in R176Q: 1.6 ± 0.21 vs control: 1.6 ± 0.44; P = .94)

were karyotyped and exhibited normal chromosomal archi-

(Figure 2E) and total SR Ca2+ load (F/F0 in R176Q: 2.3 ± 0.36 vs

tectures (Figure S2E). The cells were genetically sequenced

control: 2.1 ± 0.43; P = .76) (Figure 2F) was similar amongst the

and the mutant variant (G > A) was found to be present in

groups. Together, these results show that systolic SR Ca2+ handling

the proband-d erived iPSCs but not in those derived from the

was similar between R176Q and control iPSC-CMS, while aberrant

control individual (Figure S2F). The pluripotency of the cells

diastolic SR Ca2+ release events were seen exclusively in iPSC-CM

was validated using fluorescence-a ctivated cell sorting (FACS)

from the CPVT patient.

|
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F I G U R E 2 Systolic Ca2+ transients in control and R176Q proband-derived induced pluripotent stem cell-derived cardiomyocytes (iPSC-
CMs) under baseline conditions. A, Confocal line-scan images (top) and Ca2+ transients (bottom) in iPSC-CMs from the proband with the
R176Q variant and healthy control under baseline conditions. Red arrows indicate spontaneous SR Ca2+ release events that developed
during the diastolic phase in PSC-CMs from the proband. Bar graph summarizing non-evoked B, Ca2+ transient amplitude and C, 10 mmol/L
caffeine-induced SR Load under baseline conditions of control (black) and R176Q (red) iPSC-CMs. D, Confocal line-scan images (upper
panel) and transients (bottom panel) showing intracellular Ca2+ handling loaded with fluro-4-AM of evoked (1-Hz field stimulation) control
vs R176Q iPSC-CMs at baseline. DADs were further exacerbated in stimulated R176Q iPSC-CMs. Bar graph summarizing evoked E, Ca2+
transient amplitude and F, 10 mmol/L caffeine-induced SR Load under baseline conditions. Open circles represent individual cells. Data
presented as mean ± SEM (NS = not statistically significant)

3.4 | Isoproterenol generates EADs in R176Q iPSC-
CMs spontaneous and evoked Ca2+ transients

iPSC-CMs after ISO stimulation. The amplitude of the Ca2+ transients (F/F0 in R176Q: 2.2 ± 1.5 vs control: 2.7 ± 0.89; P = .63) was

similar amongst the two groups (Figure 3E). However, the SR Ca2+

To simulate β-adrenergic stimulation conditions that provoke arrhythmias in CPVT patients, 100 nmol/L isoproterenol (ISO) was

load was significantly lower in R176Q iPSC-CM (F/F0: 1.8 ± 0.37)
compared with control iPSC-CMs (F/F0: 3.9 ± 0.64; P = .039), sug-

added to the iPSC-CMs. Addition of ISO led to a positive chrono-

gesting that the oscillating SR Ca2+ release events interfere with SR

tropic response compared to baseline conditions, as typically seen

Ca2+ refilling.

in healthy iPSC-CMs. 20 The average spontaneous beating rate of
non-evoked iPSC-CMs with the R176Q mutation was 122.3 ± 18.1
/minutes vs control iPSC-CMs 35.4 ± 5.2 (P = .002). 53% of the
iPSC-CMs with the R176Q variant exhibited abnormal SR Ca

2+

3.5 | Effect of EL20 Ca2+ sparks in iPSC-CMs

re-

lease events during the final phase of SR Ca2+ reuptake, compared

Ca2+ sparks were recorded using line-scan mode on a LSM880

to 0% of the control cells (P < .05) (Figure 3A). The amplitudes of

confocal microscope to determine the diastolic activity of RyR2 in

non-evoked Ca2+ transients were similar between the groups (F/F0

iPSC-CMs following a 1-Hz conditioning pacing train. Because spon-

in R176Q: 1.7 ± 0.45 vs control: 1.9 ± 0.37; P = .78) (Figure 3B). The

taneous contractions in the non-evoked iPSC-CM population can

SR Ca2+ load was found to be similar between both groups (F/F0 in

potentially confound diastolic Ca2+ releases, Ca2+ imaging was done

R176Q: 2.7 ± 0.52 vs control: 3.3 ± 0.42 and P = .53) (Figure 3C).

only under evoked pacing conditions to profile the drug responses

About 75% of the iPSC-CMs that did not spontaneously beat

of EL20 in vitro. In the presence of 100 nmol/L ISO, iPSC with the

did generate SR Ca2+ transients following the 1-Hz pacing train

R176Q mutation exhibited a higher Ca2+ spark frequency (CaSpF)

(Figure 3D). While similar number of iPSC-CMs with the R176Q

(3.6 ± 0.45 sparks/100 μm/s) compared with iPSC from the control

variant responded to electrical stimulation, 71% (5 of 7) of those

(1.2 ± 0.34 sparks/100 μm/s; P < .001) (Figure 4A,B). Next, a screen-

iPSC-CMs exhibited distinct oscillating SR Ca2+ release patterns

ing dose of 500 nmol/L of EL20 was applied to the cells to determine

that originated early during the Ca2+ transient recovery phase.

the effects of this RyR2 inhibitor on diastolic SR Ca2+ release events.

These abnormalities were not observed in any of the control

In control iPSC-CMs, the CaSpF was not significantly affected by the

6
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F I G U R E 3 Effects of isoproterenol on systolic Ca2+ transients in control and R176Q-proband-derived induced pluripotent stem cell-
derived cardiomyocytes (iPSC-CMs) under baseline conditions. A, Confocal line-scan images (top) and Ca2+ transients (bottom) in iPSC-CMs
from the proband with the R176Q variant and healthy control in the presence of 100-nmol/L isoproterenol (ISO). Red arrows indicate
spontaneous SR Ca2+ release events that developed during the diastolic phase in PSC-CMs from the proband. Bar graph summarizing non-
evoked B, Ca2+ transient amplitude and C, 10 mmol/L caffeine-induced SR Load under baseline conditions of control (black) and R176Q (red)
iPSC-CMs. D, Confocal line-scan images (upper panel) and transients (bottom panel) showing intracellular Ca2+ handling loaded with fluro-
4-AM of evoked (1-Hz field stimulation) control vs R176Q iPSC-CMs in the presence of 100-nmol/L isoproterenol (ISO). SR Ca2+ oscillations
were further exacerbated in stimulated R176Q iPSC-CMs. Bar graph summarizing evoked E, Ca2+ transient amplitude and F, 10 mmol/L
caffeine-induced SR Ca2+ load in the presence of 100-nmol/L ISO. Open circles represent individual cells. Data presented as mean ± SEM
(*P < .05; NS = not statistically significant)

addition of EL20 (1.3 ± 0.44 sparks/100 μm/s; P = .92 vs vehicle). In

Ca2+ transients consequently leading to unwanted side effects. 21

contrast, in R176Q iPSC-CMs, EL20 significantly reduced the CaSpF

To address this concern, we measured the Ca2+ transient amplitude

by 78% (to 0.8 ± 0.45 sparks/100 μm/s; P < .001 vs vehicle).

induced by field stimulation at 1-Hz in iPSC-CMs (Figure 5). The amplitude of the SR Ca2+ transient was not altered by EL20 in iPSC-CMs
from the control (F/F0: 1.8 ± 0.46) compared to control + vehicle

3.6 | Dose-response of Ca2+ spark inhibition
by EL20

(F/F0: 1.9 ± 0.27; P = .91). Importantly, EL20 also did not alter the

Ca2+ transient amplitude in R176Q iPSC-CMs (F/F0: 1.7 ± 0.20) com-

pared to R176Q + vehicle (F/F0: 1.9 ± 0.46; P = .79). Interestingly,
To get a better sense of what drug concentrations are needed to inhibit

treatment with EL20 prevented to occurrence of pacing-evoked

mutant RyR2 channels, we assessed the effects of different doses of

Ca2+ oscillations (Figure 3D), consistent with inhibition of aberrant

EL20 on CaSpF in evoked iPSC-CMs derived from the CPVT proband.

RyR2 SR Ca2+ leak. Thus, EL20 does not negatively affect the Ca2+

The dose-response curve, which is based on inhibition of the CaSpF,

transient amplitude at the cellular level, as previously seen in the

was determined at concentrations ranging from 10

−9

−4

up to 10 mol/L

CPVT mouse model.12

(Figure 4C). Results from the sigmoidal dose-response curve determined that the half maximal inhibitory concentration (IC50) of EL20 is

8.2 × 10−8 mol/L. Hence, EL20 was found to inhibit excessive SR Ca2+

4 | D I S CU S S I O N

release at low nanomolar concentrations that are clinically relevant.
Catecholaminergic polymorphic ventricular tachycardia re-

3.7 | Absence of detrimental effects of EL20 on
systolic SR Ca2+ handling

mains a difficult to treat inherited cardiac disorder associated
with arrhythmias provoked by adrenergic stress. As reviewed in
great detail in this recent review article,9 various classes of anti-
arrhythmic drugs with RyR2 inhibitory properties have been

Since EL20 inhibits aberrant SR Ca2+ release through mutant RyR2,

developed and some show great promise for the treatment of

it is possible that this drug has unwanted effects on systolic SR

CPVT. Patient-d erived induced pluripotent stem cell-d erived

|
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cardiomyocytes (hiPSC-C Ms) offer a powerful cellular model to

in spontaneously beating and paced single iPSC-C Ms contain-

evaluate the potential effectiveness and safety of experimental

ing the R176Q variant in RyR2. Moreover, tetracaine deriva-

drugs in a preclinical human cell model. 22 In the present study,

tive EL20 was able to suppress these aberrant SR Ca 2+ release

we developed and characterized a novel iPSC-C M cell line con-

events at low nanomolar doses, suggesting that EL20 and re-

taining an N-t erminal variant R176Q in RyR2. Our studies re-

lated compounds are promising agents for the treatment of

vealed evidence for abnormal diastolic SR Ca

2+

release events

CPVT patients.

4.1 | Preclinical CPVT models based on iPSC-CMs
Patient-specific induced pluripotent stem cell-derived cardiomyocytes have emerged as a powerful model of inherited arrhythmia
disorders after the development of stem cell reprogramming by
Yamanaka et al23 iPSC-CMs containing various CPVT-associated
RyR2 variants have been generated and studies using confocal imaging and patch-clamping approaches. Most studies to date revealed
altered intracellular Ca2+ handling, in particular during final stages of
repolarization, and increased Ca2+ spark frequencies, in iPSC-CMs
containing RyR2 variants. 24 Consistent with clinical observations,
the administration of β-adrenergic agonists exacerbated these Ca2+

abnormalities in most studies. Jung et al25 investigated intracellular

Ca2+ handling in great detail in CPVT iPSC-CM and found evidence
for increased diastolic SR Ca2+ leak as well as reduced SR Ca2+ store
contents after tonic stimulation. Our studies revealed similar findings including an increased SR Ca2+ spark frequency and reduced
SR Ca2+ load after β-adrenergic stimulation. These data suggest that

enhanced diastolic SR Ca2+ leak in particular during β-adrenergic
F I G U R E 4 EL20 suppresses abnormal SR Ca2+ release events
in induced pluripotent stem cell-derived cardiomyocytes (iPSC-
CMs) derived from the catecholaminergic polymorphic ventricular
tachycardia patient (CPVT) proband. A, Representative recordings
of Ca2+ sparks in iPSC-CMs from the CPVT proband in the absence
and presence of EL20 (500-nmol/L). B, Summary data showing that
EL20 reduced the Ca2+ spark frequency (CaSpF) in stimulated iPSC-
CM compared to vehicle treatment. C, Dose-dependence of Ca2+
spark frequency inhibition and IC50 determination of EL20 (n = 9-
10 cells per group). Open circles represent individual cells. Data
presented as mean ± SEM (*P < .05, **P < .01, and ***P < .001)

stimulation is the primary mechanism underlying arrhythmia formation, rather than SR Ca2+ overload which has been proposed as one
mechanism of CPVT by some authors. 26,27
In this study, we developed iPSC-CMs derived from a 14-year-old
girl with the same N-terminal RyR2 variant R176Q as the mouse
model previously reported by us.13,18 The R176Q variant caused
a highly penetrant and severe phenotype in this affected family
(Figure 1). The father, who is negative for the RyR2 variant, was
the donor for the control iPSC-CM cell line. Characterization of
intracellular Ca2+ handling in the control iPSC-CMs revealed no

F I G U R E 5 Absence of detrimental effects on evoked systolic SR Ca2+ transients by EL20. A, Confocal line-scan images (top) and
transients (bottom) showing intracellular Ca2+ transients recorded in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs)
loaded with fluro-4-AM during 1-Hz field stimulation pacing in the presence 500-nmol/L EL20. B, Bar graph summarizing the Ca2+ transient
amplitude in iPSCs from both the catecholaminergic polymorphic ventricular tachycardia patient proband and control individual. Open
circles represent individual cells. Data presented as mean ± SEM (NS = not statistically significant.)
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abnormalities, confirming the specificity and validity of the CPVT

Ca2+ load. Together, these findings indicate that EL20 directly in-

iPSC-CM cell line. The iPSC-CM containing the R176Q variant exhib-

hibits diastolic SR Ca2+ release events through the R176Q mutant

ited several distinct abnormalities in intracellular Ca

2+

handling. In

RyR2 channels.

spontaneously beating as well as pacing cells, spontaneous SR Ca2+

Previous studies revealed that EL20 stabilizes hyperactive RyR2

release events were seen during the late and early Ca2+ reuptake

channels.13 The molecular mechanism underlying the therapeutic

phase of the Ca2+ transient. The events during early repolarization

effects of EL20 is believed to involve stabilization of the mutant

look similar to oscillatory events associated with EADs in other

RyR2 channel from which calmodulin has been dissociated as a re-

studies in which action potentials were measured in iPSC-CMs. 28,29

sult of the CPVT variant.13 On the other hand, EL20 did not alter

These events more predominantly seen following b-adrenergic stim-

the activity of wild-t ype RyR2 channel to which normal amounts

release events were observed

of calmodulin are bound.13 Future studies can be conducted to

after or during the final repolarization phase, consistent with DADs.

validate this model by overexpressing calmodulin or generating

These findings are consistent with prior studies and recapitulate

calmodulin variants that enhance its binding to RyR2 containing

the CPVT phenotype within the iPSC-CM model. 28 Patients with

CPVT-associated variants. Regardless, the observation that EL20

RyR2 variants can be susceptible to both EAD- and DAD-mediated

and likely other tetracaine derivatives only modulate RyR2 chan-

arrhythmia mechanisms because membrane voltage is strongly influ-

nels containing disease-associated variants is promising and sug-

enced by Ca2+-sensitive ionic currents, and, conversely, cellular Ca2+

gests that these drugs will lack significant side effects, in particular

loading is strongly influenced by Ca2+ voltage-dependent currents

suppression of excitation-contraction coupling and reduced cardiac

ulation. In addition, aberrant SR Ca

2+

that can promote complex AP dynamics in the heart.

30

The diastolic

contractility.

SR Ca2+ leak can activate the Na+/Ca2+-exchanger, leading to a net
inward Na+ current that can depolarize the plasma membrane leading to an arrhythmogenic beat.

4.2 | EL20 prevents arrhythmogenic Ca2+ release
events in CPVT iPSC-CMs

5 | CO N C LU S I O N S
We found that iPSC-CMs derived from a CPVT patient carrying
RyR2 variant R176Q display irregular spontaneous Ca2+ release
events that are well-established triggers of arrhythmias. Our data
show that EL20 eliminated cellular arrhythmias at nanomolar con-

Several prior studies showed that iPSC-CMs derived from CPVT

centrations in the absence of obvious side effects on intracellular

patients can be utilized to identify drug molecules that correct

Ca2+ handling parameters examined in the iPSC-CMs. Therefore,

the cellular phenotypes associated with mutant RyR2. 24 In prior

EL20 is a promising lead compound for further drug development

work, we synthesized a novel tetracaine derivative known as EL20

efforts that could potentially provide novel treatment options for

and tested its pharmacological properties in the RyR2-R176Q het-

the orphan disease CPVT. RyR2 inhibitors such as EL20 directly tar-

erozygous mouse model of CPVT.13 EL20 prevented ventricular

get the disease-causing molecular defect in patients with CPVT (ie

tachycardia in R176Q/+ mice. Another tetracaine derivative known

leaky RyR2 channels) and could be more effective compared to beta

as EL9 also suppressed VT in the R176Q/+ mouse model without

blockers that work upstream in the beta-adrenergic receptor signal-

adverse effects on cardiac contractility.12 In ventricular myocytes

ling pathway that leads to RyR2 phosphorylation and exacerbation

isolated from R176Q/+ mice, EL9 normalized the increased Ca2+

of SR Ca2+ leak during stress or exercise.31 In a patient with a very

spark frequency with an IC 50 of 13 nmol/L.12 These findings in ven-

high arrhythmic burden, however, it might be beneficial to treat with

tricular myocytes isolated from a CPVT mouse model were quite

both EL20 and beta blockers to prevent SR Ca2+ leak at multiple lev-

similar to those reported for EL20 in iPSC-CMs carrying the iden-

els in the signalling pathway. In conclusion, our patient-derived iPSC-

tical RyR2 variant R176Q. The present study represents the first

CM model offers a promising platform for further research into the

to characterize the effects of a tetracaine derivative with RyR2

pathophysiological mechanisms of CPVT, as well as a safe tool for

inhibiting activity (ie EL20) on intracellular Ca

2+

handling proper-

screening and optimizing drug therapy using novel RyR2 inhibitors.

ties in human cardiomyocytes. Our work reveals that EL20 can
normalize intracellular Ca2+ handling at nanomolar concentrations

AC K N OW L E D G E M E N T S

and prevented cellular arrhythmogenesis in iPSC-CM from a CPVT

The compound EL20 was provided by Elex Biotech, Inc (Portland,

patient (Figure S6). On the other hand, EL20 did not exhibit un-

OR).

wanted effects in control iPSC-CMs derived from the proband's
father who is negative for the RyR2 variant. Moreover, EL20 did

C O N FL I C T O F I N T E R E S T

not affect systolic SR Ca2+ release as evidenced by unaltered Ca2+

RMS and XHTW are founding partners of Elex Biotech, a start-up

transient amplitudes (Figure 5). Since there was no difference in SR

company that developed drug molecules to target ryanodine recep-

Ca2+ load between control and R176Q cells under basal conditions

tors for treatment of cardiac arrhythmias. Other authors have no

(Figure 2C), we are quite confident that EL20 does not alter the SR

conflicts related to this study.
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